Pharmaceutical company AbbVie has announced positive topline results from its Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease.
Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson’s disease.
The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose between 5 mg to 15 mg, once daily treatment with tavapadon as a monotherapy in adults with early Parkinson’s disease.
The company has stated that the trial met its primary endpoint, with patients treated with tavapadon experiencing a statistically significant improvement from baseline compared to placebo in the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26.
The TEMPO-2 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living in the tavapadon group compared to placebo at week 26.
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 partial agonist for the treatment of Parkinson’s disease,” said Primal Kaur, senior vice president, immunology, neuroscience, eye care and specialty development at AbbVie.
“With these data in hand, we look forward to working with regulatory agencies to assess next steps, bringing us one step closer to providing tavapadon for those living with this chronic, debilitating disease.”
The safety profile observed in the TEMPO-2 trial was consistent with prior clinical trials and the majority of adverse events reported were mild to moderate in severity.
“Parkinson’s disease imposes a profound burden on individuals living with this challenging neurological condition, significantly affecting their quality of life and management of daily activities. Right now, there is still an unmet need for treatments that deliver efficacy while minimizing unwanted side effects,” said Hubert H. Fernandez, M.D., global principal investigator.
“The results from TEMPO-2, and across the entire TEMPO clinical development program, add to the growing evidence which suggests that tavapadon has the potential to offer an important new option for individuals living with Parkinson’s disease.”
Full results from the TEMPO-2 trial will be submitted for presentation at a future medical meeting. AbbVie is on track to submit the New Drug Application to the U.S. Food & Drug Administration in 2025.
